Posted inHealth

Zanubrutinib Better Than Ibrutinib in CLL/SLL?

Zanubrutinib (Brukinsa), a second-generation Bruton tyrosine kinase (BTK) inhibitor, has shown a significantly greater delay in disease progression vs the standard of care ibrutinib (Imbruvica) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with equally encouraging reductions in adverse events. The findings come from a preplanned interim analysis of the global, […]